Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07327632 | This is a Multi-Center Study of IBI3026 in Participants With Locally Advanced, Unresectable or Metastatic Solid Tumors | recruiting | Early Phase 1 | 300 | Innovent Biologics Technology Limited (Shanghai R&D Center)INDUSTRY | 1 | Feb 4, 2026 | clinicaltrials |
| NCT07382531 | OH2 Injection in Combination With BS006 Injection for Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 30 | Binhui Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 4, 2026 |
| clinicaltrials |
| NCT06697197 | A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 413 | Bristol-Myers SquibbINDUSTRY | 9 | Feb 3, 2026 | clinicaltrials |
| NCT07215637 | Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 60 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT07381179 | Voices: Messages of Wisdom and Hope in the Face of Illness | recruiting | — | 40 | Mayo ClinicOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT04390737 | Evaluate the Safety and Clinical Activity of HH2853 | recruiting | Phase 1 / Phase 2 | 254 | Haihe Biopharma Co., Ltd.INDUSTRY | 2 | Jan 30, 2026 | clinicaltrials |
| NCT05584449 | Group Curriculum for Improving Survivorship Outcomes in Adolescent and Young Adult Cancer Survivors | recruiting | N/A | 60 | Mayo ClinicOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT06809114 | FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors | recruiting | Phase 1 | 83 | Axcynsis Therapeutics Pte LtdINDUSTRY | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07377591 | A Study of HDM2006 in Patients With Advanced Solid Tumor | recruiting | Phase 1 | 48 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 30, 2026 | clinicaltrials |
| NCT06644300 | Study of BM230 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 123 | Suzhou Biomissile Pharmaceuticals Co., Ltd.INDUSTRY | 2 | Jan 29, 2026 | clinicaltrials |
| NCT07148128 | Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours. | recruiting | Phase 1 / Phase 2 | 110 | Auricula Biosciences Inc.INDUSTRY | 3 | Jan 29, 2026 | clinicaltrials |
| NCT05371132 | Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR) | recruiting | Phase 1 | 10 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06208657 | Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer | recruiting | Phase 1 / Phase 2 | 90 | Australian & New Zealand Children's Haematology/Oncology GroupOTHER | 2 | Jan 28, 2026 | clinicaltrials |
| NCT06484985 | Study of AXT-1003 in Subjects With Advanced Malignant Tumors. | recruiting | Phase 1 | 78 | Axter Therapeutics (Beijing) Co., LtdINDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07151040 | Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors(ODIN) | recruiting | Phase 1 / Phase 2 | 43 | One-carbon Therapeutics ABINDUSTRY | 3 | Jan 28, 2026 | clinicaltrials |
| NCT07357636 | Longitudinal Cohort Study of Immune-Related Adverse Events in Solid Tumor Patients Treated With Immune Checkpoint Inhibitors | recruiting | — | 940 | Shantou University Medical CollegeOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07371663 | An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 266 | Beijing Tide Pharmaceutical Co., LtdINDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT05867420 | A Study of ASKG915 in Patients With Selected Advanced Solid Tumors. | recruiting | Phase 1 / Phase 2 | 594 | AskGene Pharma, Inc.INDUSTRY | 2 | Jan 27, 2026 | clinicaltrials |
| NCT06397963 | Autologous Tumor-Infiltrating Lymphocyte (GT307 Injection ) for Treatment of Patients With Solid Tumours | recruiting | N/A | 18 | Grit BiotechnologyINDUSTRY | 1 | Jan 26, 2026 | clinicaltrials |
| NCT07348211 | First in Human Study of SIM0610 in Solid Tumors(SIM0610-101) | recruiting | Phase 1 | 260 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07093970 | A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 343 | Lepu Biopharma Co., Ltd.INDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07358806 | Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 51 | Oscotec Inc.INDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT06503783 | A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors | recruiting | Phase 1 | 20 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06609187 | A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors | recruiting | Phase 1 | 20 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06612840 | A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid Tumors | recruiting | Phase 1 | 20 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07242417 | TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors | recruiting | Early Phase 1 | 30 | Beijing GoBroad HospitalOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07291414 | A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients | recruiting | N/A | 80 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06959615 | A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration | recruiting | Phase 1 / Phase 2 | 334 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 20, 2026 | clinicaltrials |
| NCT07146074 | Early Radiotherapy Versus Observation for High-risk Asymptomatic or Minimally Symptomatic Bone Metastases(HERMES) | recruiting | N/A | 120 | Cancer Research AntwerpOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT07351903 | A Single-arm, Open-label Study of GK01 in Combination With or Without Chemotherapy for the Adjuvant Treatment of Solid Tumors(GUARDIAN-02) | recruiting | Phase 1 | 15 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT06302426 | Trial of INI-4001 in Patients With Advanced Solid Tumours | recruiting | Phase 1 | 50 | Inimmune CorporationINDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT06927570 | A Study of HS-20122 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 1,050 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT06973564 | JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration | recruiting | Phase 1 / Phase 2 | 294 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07186452 | Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 18 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07231458 | A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies | recruiting | Phase 1 | 27 | Abalos Therapeutics GmbHINDUSTRY | 2 | Jan 16, 2026 | clinicaltrials |
| NCT07348042 | Study of RGL-270 Single Drug and Combined With Adebelimab in Patients in Patients at High Risk of Recurrence After Radical Treatment of Malignant Solid Tumors | recruiting | Phase 1 | 198 | Xian-Jun YuOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07349160 | Safety and Efficacy of Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors | recruiting | Early Phase 1 | 36 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07275242 | A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid Tumor | recruiting | Phase 1 | 107 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 15, 2026 | clinicaltrials |
| NCT06234423 | A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors | recruiting | Phase 1 | 263 | OnCusp Therapeutics, Inc.INDUSTRY | 2 | Jan 14, 2026 | clinicaltrials |
| NCT07253116 | A Phase I/II Clinical Study of WJ22096 Tablets in Patients With Advanced Tumors | recruiting | Phase 1 / Phase 2 | 20 | Nanjing Jingao biomidical technology Co. Ltd.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT05006482 | Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial(GEM-S) | recruiting | Phase 3 | 668 | University of RochesterOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT06414278 | Evaluation of Early Identification of Cognitive Side Effects of Immunotherapy | recruiting | — | 38 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT03829254 | A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma | recruiting | Phase 1 / Phase 2 | 135 | NuCana plcOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT06887348 | A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3(RPx) | recruiting | — | 50 | Replimune, Inc.INDUSTRY | 2 | Jan 12, 2026 | clinicaltrials |
| NCT07268040 | A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors | recruiting | Phase 2 | 400 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT07312903 | DPTX3186 in Wnt Pathway Activated Solid Tumors | recruiting | Phase 1 | 40 | Dewpoint TherapeuticsINDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT05490472 | JAB-2485 Activity in Adult Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 102 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 2 | Jan 9, 2026 | clinicaltrials |
| NCT06737731 | A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 300 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT07258160 | Evaluation of the Effect of Cordycepin on CD8+ Lymphocytopenia in Patients With Solid Tumors | recruiting | Phase 2 | 127 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT06265727 | A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors | recruiting | Phase 1 / Phase 2 | 348 | Corbus Pharmaceuticals Inc.INDUSTRY | 7 | Jan 8, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Feb 4, 2026source: clinicaltrials